The significance of epigenetic alterations in lung carcinogenesis

Molecular Biology Reports

Volumn 40, Issue 1, 2013, Pages 309-325

  Brzeziańska, Ewa ^a   Dutkowska, Agata ^a   Antczak, Adam ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Epigenetic modifications; Histone modifications; Lung cancer; miRNA; Promoter hypermethylation

Indexed keywords

BIOLOGICAL MARKER; DNA METHYLTRANSFERASE; MICRORNA; UNTRANSLATED RNA;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; DNA MODIFICATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HISTONE MODIFICATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; ONCOGENE; PERSONALIZED MEDICINE; PHENOTYPE; RETROPOSON; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84871282536     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2063-4     Document Type: Article

References (178)

1. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-692
2. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7:21-33
3. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5:e114
4. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054
5. Feinberg AP (2001) Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 98:392-394
6. Brena RM, Costello JF (2007) Genome-epigenome interactions in cancer. Hum Mol Genet 16:R96-R105
7. Jacinto FV, Esteller M (2007) Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22:247-253
8. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27-36
9. Holliday R (2006) Epigenetics: a historical overview. Epigenetics 1:76-80
10. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597-610
11. Vaissière T, Sawan C, Herceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659:40-48
12. Robertson KD (2002) DNA methylation and chromatin-unraveling the tangled web. Oncogene 21:5361-5379
13. Hendrickson DG, Hogan DJ, McCullough HL, Myers JW, Herschlag D, Ferrell JE, Brown PO (2009) Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol 7:e1000238
14. Xing M (2008) Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41:1135-1146
15. Kondo Y (2009) Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 50:455-463
16. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074-1080
17. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705
18. Cheung P, Lau P (2005) Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 19:563-573
19. Kouzarides T (2002) Histone methylation in transcriptional control. Curr Opin Genet Dev 12:198-209
20. Berger SL (2007) The complex language of chromatin regulation during transcription. Nature 447:407-412
21. Kim GD, Ni J, Kelesoglu N, Roberts RJ, Pradhan S (2002) Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 21:4183-4195
22. Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9:2395-2402
23. Kanai Y, Hirohashi S (2007) Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28:2434-2442
24. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21
25. Mossman D, Kim KT, Scott RJ (2010) Demethylation by 5-aza-2′- deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10:366
26. Palii SS, Robertson KD (2007) Epigenetic control of tumor suppression. Crit Rev Eukaryot Gene Expr 17:295-316
27. Xing M (2007) Gene methylation in thyroid tumorigenesis. Endocrinology 148(3):948-953
28. D'Alessio AC, Szyf M (2006) Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 84:463-476
29. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M (2007) Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67:1424-1429
30. Weber B, Stresemann C, Brueckner B, Lyko F (2007) Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 6:1001-1005
31. Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, Kreipe H (2008) Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214:17-24
32. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 66:1277-1281
33. Jones PA (1996) DNA methylation errors and cancer. Cancer Res 56:2463-2467
34. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG (2001) Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 61:7034-7038
35. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-5413
36. Costello JF, Frühwald MC, Smiraglia DJ et al (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138
37. Ehrlich M (2009) DNA hypomethylation in cancer cells. Epigenomics 1:239-259
38. Dunn BK (2003) Hypomethylation: one side of a larger picture. Ann NY Acad Sci 983:28-42
39. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148-1159
40. Kanai Y (2010) Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 101:36-45
41. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K (2008) Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology 75:145-151
42. Park SY, Kim BH, Kim JH, Cho NY, Choi M, Yu EJ, Lee S, Kang GH (2007) Methylation profiles of CpG island loci in major types of human cancers. J Korean Med Sci 22:311-317
43. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jerónimo C (2007) Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7:133
44. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3:e486
45. Singal R, Ferdinand L, Reis IM, Schlesselman JJ (2004) Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 12:631-637
46. Wong IH, Chan J, Wong J, Tam PK (2004) Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 10:994-1002
47. Psofaki V, Kalogera C, Tzambouras N, Stephanou D, Tsianos E, Seferiadis K, Kolios G (2010) Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol 16:3553-3560
48. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y (2009) Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 30:214-221
49. Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y (2009) Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 125:2854-2862
50. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA (2008) Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer 7:94
51. Euhus DM, Bu D, Milchgrub S, Xie XJ, Bian A, Leitch AM, Lewis CM (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17:1051-1059
52. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E (2007) Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 20:1269-1277
53. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S (2006) Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 119:288-296
54. Hoque MO, Rosenbaum E, Westra WH, Xing M, Ladenson P, Zeiger MA, Sidransky D, Umbricht CB (2005) Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 90:4011-4018
55. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A (2002) CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 160:1823-1830
56. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR (2000) Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 60:4346-4348
57. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681-8686
58. Jing F, Yuping W, Yong C, Jie L, Jun L, Xuanbing T, Lihua H (2010) CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma. Tumour Biol 31:321-331
59. Liu Z, Li W, Lei Z, Zhao J, Chen XF, Liu R, Peng X, Wu ZH, Chen J, Liu H, Zhou QH, Zhang HT (2010) CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer. J Thorac Oncol 5:790-797
60. Park SY, Kook MC, Kim YW, Cho NY, Jung N, Kwon HJ, Kim TY, Kang GH (2010) CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch 457:415-422
61. Yang XJ, Seto E (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:5310-5318
62. Kim GW, Yang XJ (2011) Comprehensive lysine acetylomes emerging from bacteria to humans. Trends Biochem Sci 36:211-220
63. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295-304
64. Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420-5432
65. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H (2003) Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 983:220-231
66. Valk-Lingbeek ME, Bruggeman SW, Van Lohuizen M (2004) Stem cells and cancer; the polycomb connection. Cell 118:409-418
67. Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR (2011) Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol 6:1179-1189
68. Cadieux B, Ching TT, Vandenberg SR, Costello JF (2006) Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66:8469-8476
69. Kurdistani SK (2011) Histone modifications in cancer biology and prognosis. Prog Drug Res 67:91-106
70. Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation: microRNAs can up-regulate translation. Science 318:1931-1934
71. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866
72. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M (2009) Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34:1069-1075
73. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756
74. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999-3004
75. Melo SA, Esteller M (2011) A precursor microRNA in a cancer cell nucleus: get me out of here! Cell Cycle 10:922-925
76. Bueno MJ, Pérez de Castro I, Gómez de Cedrón M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernández-Piqueras J, Malumbres M (2008) Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13:496-506
77. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T (2008) Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68:4123-4132
78. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68(7):2094-2105
79. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 379:726-731
80. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J (2010) MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(5):766-776
81. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sültmann H, Lyko F (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67:1419-1423
82. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443
83. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J (2009) Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125:2737-2743
84. Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585:2087-2099
85. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10-29
86. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) Pathology and genetics. WHO Classification of tumours: tumours of the lung, pleura, thymus and heart, chap 1. IARC Press, Lyon
87. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary-classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
88. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89-92
89. Wilson AS, Power BE, Molloy PL (2007) DNA hypomethylation and human diseases. Biochim Biophys Acta 1775:138-162
90. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100:1734-1738
91. Pattamadilok J, Huapai N, Rattanatanyong P, Vasurattana A, Triratanachat S, Tresukosol D, Mutirangura A (2008) LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer 18:711-717
92. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Cervantes F, Sanchez J, Garate L, Barrios M, Castillejo JA, Navarro G, Colomer D, Prosper F, Heiniger A, Torres A (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24:7213-7223
93. Pavicic W, Joensuu EI, Nieminen T, Peltomäki P (2012) LINE-1 hypomethylation in familial and sporadic cancer. J Mol Med (Berl) [Epub ahead of print]
94. Piskareva O, Lackington W, Lemass D, Hendrick C, Doolan P, Barron N (2011) The human L1 element: a potential biomarker in cancer prognosis, current status and future directions. The human L1 element: a potential biomarker in cancer prognosis, current status and future directions. Curr Mol Med 11:286-303
95. Kazazian HH Jr, Goodier JL (2002) LINE drive. retrotransposition and genome instability. Cell 110:277-280
96. Symer DE, Connelly C, Szak ST, Caputo EM, Cost GJ, Parmigiani G, Boeke JD (2002) Human L1 retrotransposition is associated with genetic instability in vivo. Cell 110:327-338
97. Choma D, Daures JP, Quantin X, Pujol JL (2001) Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer 85:14-22
98. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T (2010) Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res 16:2418-2426
99. Daskalos A, Logotheti S, Markopoulou S, Xinarianos G, Gosney JR, Kastania AN, Zoumpourlis V, Field JK, Liloglou T (2011) Global DNA hypomethylation- induced ΔNp73 transcriptional activation in non-small cell lung cancer. Cancer Lett 300:79-86
100. Glazer CA, Smith IM, Ochs MF, Begum S, Westra W, Chang SS, Sun W, Bhan S, Khan Z, Ahrendt S, Califano JA (2009) Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS ONE 4:e8189
101. Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M, Zur Hausen A (2011) Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 43:719-724
102. Klenova EM, Morse HC 3rd, Ohlsson R, Lobanenkov VV (2002) The novel BORIS+CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12:399-414
103. Pugacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsov E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V (2010) The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS ONE 5:e13872
104. Martin-Kleiner I (2011) BORIS in human cancers-a review. Eur J Cancer [Epub ahead of print]
105. Renaud S, Pugacheva EM, Delgado DM, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V (2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 35:7372-7388
106. Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, Gaykalova DA, Sun W, Sidransky D, Ha PK, Califano JA (2011) BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 17:4267-4276
107. Fiorentino FP, Macaluso M, Miranda F et al (2011) CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 9:225-233
108. Radhakrishnan VM, Jensen TJ, Cui H, Futscher BW, Martinez JD (2011) Hypomethylation of the 14-3-3? promoter leads to increased expression in non-small cell lung cancer. Genes Chromosomes Cancer 50:830-836
109. Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75:173-234
110. Gu Y, Wang C, Wang Y, Qiu X, Wang E (2009) Expression of thymosin beta10 and its role in non-small cell lung cancer. Hum Pathol 40:117-124
111. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB (2003) Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33:197-202
112. Kwon YJ, Lee SJ, Koh JS, Kim SH, Lee HW, Kang MC, Bae JB, Kim YJ, Park JH (2011) Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J Thorac Oncol [Epub ahead of print]
113. Cortese R, Hartmann O, Berlin K, Eckhardt F (2008) Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int J Biochem Cell Biol 40:1494-1508
114. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, Califano JA, Goodman SN, Westra WH, Hoque MO, Sidransky D (2011) An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res 17:4494-4503
115. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J, Chen L (2011) Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303:21-28
116. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T (2007) Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 58:131-138
117. Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, Jordan CD, Kiviat NB, Vesselle H (2008) DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 17:645-654
118. Tsou JA, Galler JS, Siegmund KD, Laird PW, Turla S, Cozen W, Hagen JA, Koss MN, Laird-Offringa IA (2007) Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer 6:70
119. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF (2007) Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247:56-71
120. Ji M, Guan H, Gao C, Shi B, Hou P (2011) Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 11:147
121. Anglim PP, Galler JS, Koss MN, Hagen JA, Turla S, Campan M, Weisenberger DJ, Laird PW, Siegmund KD, Laird-Offringa IA (2008) Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer 7:62
122. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Hölscher AH, Meltzer SJ, Danenberg PV (2001) Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20:3528-3532
123. Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT (2001) p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61:3419-3424
124. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT (2001) Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 20:1765-1770
125. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D (2001) Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61:1309-1313
126. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF (2003) Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103:153-160
127. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, Fabbri A, Andriani F, Brambilla C, Tavecchio L, Calarco G, Calabro E, Mancini A, Tosi D, Bossi P, Field JK, Brambilla E, Sozzi G (2009) EUELC Consortium. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am J Respir Crit Care Med 179:396-401
128. Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD, Gazdar AF (2004) Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110:462-464
129. Barlési F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25:4358-4364
130. Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B, Khochbin S, Gazzeri S (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14:7237-7245
131. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK (2009) Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174:1619-1628
132. Esteller M (2006) Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 94:179-183
133. Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25:261-309
134. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, Ogawa J (2011) Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 74:300-304
135. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13
136. Halder SK, Cho YJ, Datta A, Anumanthan G, Ham AJ, Carbone DP, Datta PK (2011) Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines. Neoplasia 13:912-922
137. Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T (2005) Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. Mol Carcinog 44:233-241
138. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98:396-406
139. Tani M, Ito J, Nishioka M, Kohno T, Tachibana K, Shiraishi M, Takenoshita S, Yokota J (2004) Correlation between histone acetylation and expression of the MYO18B gene in human lung cancer cells. Genes Chromosomes Cancer 40:146-151
140. Toyooka S, Toyooka KO, Miyajima K, Reddy JL, Toyota M, Sathyanarayana UG, Padar A, Tockman MS, Lam S, Shivapurkar N, Gazdar AF (2003) Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9:3034-3041
141. Zhong S, Fields CR, Su N, Pan YX, Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26:2621-2634
142. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39:673-677
143. Wang Z, Chen Z, Gao Y, Li N, Li B, Tan F, Tan X, Lu N, Sun Y, Sun J, Sun N, He J (2011) DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther 11:490-496
144. Incoronato M, Urso L, Portela A, Laukkanen MO, Soini Y, Quintavalle C, Keller S, Esteller M, Condorelli G (2011) Epigenetic regulation of miR-212 expression in lung cancer. PLoS ONE 6:e27722
145. Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, Choi E, Na MJ, Park JY, Kang J, Son JW (2011) Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer [Epub ahead of print]
146. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK,
147. Chuang JC, Jones PA (2007) Epigenetics and microRNAs. Pediatr Res 61:24R-29R
148. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez- Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556-13561
149. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, Bozzoni I, Caffarelli E (2007) The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 104:7957-7962
150. Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H (2011) Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 458:313-322
151. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26:5017-5022
152. Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, San José-Eneriz E, Abizanda G, Rodríguez-Otero P, Fortes P, Rifón J, Bandrés E, Calasanz MJ, Martín V, Heiniger A, Torres A, Siebert R, Román-Gomez J, Prósper F (2009) Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 69:4443-4453
153. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D (2008) miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15:272-284
154. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68:2094-2105
155. Park SM, Gaur AB, Lengyel E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22:894-907
156. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y, Hibi T (2009) Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28:2738-2744
157. Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, Mu L, Risch H, Yu H (2011) Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Res Treat 126:687-694
158. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H (2007) Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67:10117-10122
159. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, Choi KU, Kim JY, Park do Y, Sol MY (2009) Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 187:401-411
160. Lee SM, Lee WK, Kim DS, Park JY (2012) Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance. Mol Med Rep 5:239-244
161. Suzuki M, Yoshino I (2010) Aberrant methylation in non-small cell lung cancer. Surg Today 40:602-607
162. Grote HJ, Schmiemann V, Kiel S, Böcking A, Kappes R, Gabbert HE, Sarbia M (2004) Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 110:751-755
163. Li W, Deng J, Jiang P, Tang J (2010) Association of 5′-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population. Cancer Biol Ther 10:997-1000
164. Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K (2006) The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106:2190-2199
165. Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T, Mori M (2004) Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 46:305-312
166. Wistuba II, Gazdar AF, Minna JD (2001) Molecular genetics of small cell lung carcinoma. Sem Oncol 28:3-13
167. Ekim M, Caner V, Büyükpinarbaşili N, Tepeli E, Elmas L, Bagci G (2011) Determination of O6-methylguanine DNA methyltransferase promoter methylation in non-small cell lung cancer. Genet Test Mol Biomarkers 15:357-360
168. Lai JC, Cheng YW, Goan YG, Chang JT, Wu TC, Chen CY, Lee H (2008) Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. DNA Repair (Amst) 7:1352-1363
169. Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, Hölscher AH, Danenberg KD, Danenberg PV (2003) Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 9:223-227
170. Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl MP, Foerster A, Augustin F, Fiegl M, Savic S (2011) A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol 6:1649-1657
171. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126:1630-1639
172. Song H, Yi J, Zhang Y, Wang R, Chen L (2011) DNA methylation of tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14:233-238
173. Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR (2008) DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99:375-382
174. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, Mao L (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92:1511-1516
175. Niklinska W, Naumnik W, Sulewska A, Kozłowski M, Pankiewicz W, Milewski R (2009) Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 47:275-280
176. Baird AM, Gray SG, O'Byrne KJ (2011) IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer 47:1908-1918
177. Gray SG, Al-Sarraf N, Baird AM, Cathcart MC, McGovern E, O'Byrne KJ (2009) Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. Eur J Cancer 45:3087-3097
178. Fu J, Fong K, Bellacosa A, Ross E, Apostolou S, Bassi DE, Jin F, Zhang J, Cairns P, Ibañez de Caceres I, Braunewell KH, Klein-Szanto AJ (2008) VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival. PLoS ONE 3:e1698